Flow Cytometry Improved Updated Spectral Analyzer
|
By LabMedica International staff writers Posted on 31 Oct 2019 |

Image: The Aurora advanced flow cytometry system is now available with five lasers to enable seeing more than 30 colors from a single sample (Photo courtesy of Cytek Biosciences).
Flow cytometry aims to count the number, size, granularity, and other properties of cells in a heterogeneous population. Standard flow cytometry lasers excite certain fluorescent markers (fluorochromes, antibodies, or stains) on a cell as it passes through the beam.
Detectors in the instrument record and quantify the relative amount of light emitted by fluorescent markers in the cell, which the tool presents to scientists through a histogram. However, flow cytometer users can run into a myriad of technical issues, such as dealing with limited sample volumes and lacking enough lasers to excite a target amount of fluorochromes. Each laser also can only excite a certain number of fluorochromes on a cell before inducing spectral overlap.
An updated model of its Aurora flow cytometry system has been released by Cytek Biosciences (Fremont, CA, USA), which offers scientists the ability to multiplex 40 fluorescent biomarkers on a cell in a blood sample for scientific and clinical purposes. The updated Aurora platform uses five optical lasers (ultraviolet, violet, blue, yellow-green, and red) to excite 40 fluorochromes on cellular antibodies, which are then recorded by 64 detectors.
With standard flow cytometry panels, a patient's blood sample must be separated into multiple tubes to identify biomarkers linked to different types of leukemia; however the Aurora platform only needs a single tube of blood to identify the fluorescent antibodies. While scientists still need to run controls prior to running a multicolor tube to measure the different emission spectra recorded by Aurora, they can save the controls in the software and reuse them with the same panel in future tests.
Wenbin Jiang, PhD, CEO of Cytek Biosciences, said, “After chemotherapy, no one really has that many bone marrow samples available for testing and splitting into several different tubes. But because you don't need to split blood samples into several tubes with Aurora, you can have more cells per tube, which leads to more specific results." Dr. Jiang also argued that the updated Aurora system can analyze up to 30,000 to 40,000 cells per second while maintaining a "competitive sensitivity." Flow cytometry platforms on the market currently offer anywhere from 20,000 to 100,000 cells per second, but not always at the sample level of multiplexing.
Steven A. Porcelli, MD, scientific director at the Albert Einstein College of Medicine Flow Cytometry Core (Bronx, NY, USA), said, “Cytek's tool collected light coming out over a wide range of wavelengths for each cell and for each laser that we've used to excite the cell. Instead of giving you a high or low value for a tracer, it allows you to distinguish many different tracers from each other because you create a kind of fingerprint of the wavelengths being emitted.”
Related Links:
Cytek Biosciences
Albert Einstein College of Medicine Flow Cytometry Core
Detectors in the instrument record and quantify the relative amount of light emitted by fluorescent markers in the cell, which the tool presents to scientists through a histogram. However, flow cytometer users can run into a myriad of technical issues, such as dealing with limited sample volumes and lacking enough lasers to excite a target amount of fluorochromes. Each laser also can only excite a certain number of fluorochromes on a cell before inducing spectral overlap.
An updated model of its Aurora flow cytometry system has been released by Cytek Biosciences (Fremont, CA, USA), which offers scientists the ability to multiplex 40 fluorescent biomarkers on a cell in a blood sample for scientific and clinical purposes. The updated Aurora platform uses five optical lasers (ultraviolet, violet, blue, yellow-green, and red) to excite 40 fluorochromes on cellular antibodies, which are then recorded by 64 detectors.
With standard flow cytometry panels, a patient's blood sample must be separated into multiple tubes to identify biomarkers linked to different types of leukemia; however the Aurora platform only needs a single tube of blood to identify the fluorescent antibodies. While scientists still need to run controls prior to running a multicolor tube to measure the different emission spectra recorded by Aurora, they can save the controls in the software and reuse them with the same panel in future tests.
Wenbin Jiang, PhD, CEO of Cytek Biosciences, said, “After chemotherapy, no one really has that many bone marrow samples available for testing and splitting into several different tubes. But because you don't need to split blood samples into several tubes with Aurora, you can have more cells per tube, which leads to more specific results." Dr. Jiang also argued that the updated Aurora system can analyze up to 30,000 to 40,000 cells per second while maintaining a "competitive sensitivity." Flow cytometry platforms on the market currently offer anywhere from 20,000 to 100,000 cells per second, but not always at the sample level of multiplexing.
Steven A. Porcelli, MD, scientific director at the Albert Einstein College of Medicine Flow Cytometry Core (Bronx, NY, USA), said, “Cytek's tool collected light coming out over a wide range of wavelengths for each cell and for each laser that we've used to excite the cell. Instead of giving you a high or low value for a tracer, it allows you to distinguish many different tracers from each other because you create a kind of fingerprint of the wavelengths being emitted.”
Related Links:
Cytek Biosciences
Albert Einstein College of Medicine Flow Cytometry Core
Latest Technology News
- New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
- Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
- Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
- New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
- ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
- Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
- New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
- Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
- Autonomous Robotic System Receives FDA Authorization for Blood Collection
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Channels
Clinical Chemistry
view channel
Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more
Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
Lung nodules are commonly detected during chest imaging and require careful risk assessment to determine whether follow-up imaging, additional testing, or biopsy is needed. With millions of patients evaluated... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more
GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026
GeneDx (Gaithersburg, MD, USA) is presenting 27 scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montreal, Canada.... Read moreHematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read moreImmunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read morePathology
view channel
AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read moreIndustry
view channel
Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more







.jpg)